Ryser J E, Carrel S, Buchegger F, Donath A
Division of Nuclear Medicine, University Hospital of Geneva, Switzerland.
Int J Rad Appl Instrum B. 1990;17(5):487-94. doi: 10.1016/0883-2897(90)90168-z.
Biosynthetically-radiolabeled MoAbs provide a tool to test whether structural modifications of the MoAbs influence the results of conventional immunoscintigraphy. When biosynthetically-labeled 75Se-MoAbs from the Mel-14 hybridoma were injected into mice with melanoma xenografts, the high tumor recovery supported the hypothesis of a structural advantage. The increased excretion of 75Se obtained by supplementing the diet of the mice with cold selenium did not reduce the tumor recovery, demonstrating an accumulation of the free radionuclide in normal tissue.
生物合成放射性标记的单克隆抗体提供了一种工具，用于测试单克隆抗体的结构修饰是否会影响传统免疫闪烁成像的结果。当将来自Mel-14杂交瘤的生物合成标记的75Se-单克隆抗体注射到患有黑色素瘤异种移植瘤的小鼠体内时，高肿瘤摄取率支持了结构优势的假说。通过在小鼠饮食中补充冷硒而增加的75Se排泄量并没有降低肿瘤摄取率，这表明游离放射性核素在正常组织中发生了蓄积。
